Strong Specific Inhibition of UDP-glucuronosyltransferase 2B7 by Atractylenolide I and III
Authors:
- 4 November 2015
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 30 (1) , 25-30
Abstract
Drug-metabolizing enzymes inhibition-based drug–drug interaction remains to be the key limiting factor for the research and development of efficient herbal components to become clinical drugs. The present study aims to determine the inhibition of uridine 5′-diphospho-glucuronosyltransferases (UGTs) isoforms by two important efficient herbal ingredients isolated from Atractylodes macrocephala Koidz, atractylenolide I and III. In vitro recombinant UGTs-catalysed glucuronidation of 4-methylumbelliferone was used to determine the inhibition capability and kinetics of atractylenolide I and III towards UGT2B7, and in silico docking method was employed to explain the possible mechanism. Atractylenolide I and III exhibited specific inhibition towards UGT2B7, with negligible influence towards other UGT isoforms. Atractylenolide I exerted stronger inhibition potential than atractylenolide III towards UGT2B7, which is attributed to the different hydrogen bonds and hydrophobic interactions. Inhibition kinetic analysis was performed for the inhibition of atractylenolide I towards UGT2B7. Inhibition kinetic determination showed that atractylenolide I competitively inhibited UGT2B7, and inhibition kinetic parameter (Ki) was calculated to be 6.4 μM. In combination of the maximum plasma concentration of atractylenolide I after oral administration of 50 mg/kg atractylenolide I, the area under the plasma concentration-time curve ration AUCi/AUC was calculated to be 1.17, indicating the highly possible drug–drug interaction between atractylenolide I and drugs mainly undergoing UGT2B7-catalysed metabolism. Copyright © 2015 John Wiley & Sons, Ltd.Keywords
Funding Information
- National Natural Science Foundation of China (81202586, 81202587, 81202588, 81303146)
This publication has 19 references indexed in Scilit:
- Chirality Influence of Zaltoprofen Towards UDP‐Glucuronosyltransferases (UGTs) Inhibition PotentialChirality, 2015
- Glucose induces intestinal human UDP-glucuronosyltransferase (UGT) 1A1 to prevent neonatal hyperbilirubinemiaScientific Reports, 2014
- Atractylenolide-I Sensitizes Human Ovarian Cancer Cells to Paclitaxel by Blocking Activation of TLR4/MyD88-dependent PathwayScientific Reports, 2014
- A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disordersJournal of Lipid Research, 2013
- Anti-Tumor Effects of Atractylenolide I Isolated from Atractylodes macrocephala in Human Lung Carcinoma Cell LinesMolecules, 2013
- New insights for the risk of bisphenol A: Inhibition of UDP-glucuronosyltransferases (UGTs)Chemosphere, 2013
- Atractylenolide III, a sesquiterpenoid, induces apoptosis in human lung carcinoma A549 cells via mitochondria-mediated death pathwayFood and Chemical Toxicology, 2011
- Determination of propofol UDP-glucuronosyltransferase (UGT) activities in hepatic microsomes from different species by UFLC–ESI-MSJournal of Pharmaceutical and Biomedical Analysis, 2011
- Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acidsJournal of Hepatology, 2010
- Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with ZidovudineDrug Metabolism and Disposition, 2009